Blood Group Typing

Blood Group Typing

Global Blood Group Typing Market to Reach US$6.5 Billion by 2030

The global market for Blood Group Typing estimated at US$3.5 Billion in the year 2023, is expected to reach US$6.5 Billion by 2030, growing at a CAGR of 9.3% over the analysis period 2023-2030. Blood Group Typing Consumables, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Blood Group Typing Services segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$904.7 Million While China is Forecast to Grow at 13.7% CAGR

The Blood Group Typing market in the U.S. is estimated at US$904.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Blood Group Typing Market – Key Trends & Drivers Summarized

How is Blood Group Typing Evolving with Technological Advancements?

Blood group typing is an essential procedure in medical diagnostics, used primarily in blood transfusion, organ transplantation, and pregnancy management. The market for blood group typing is evolving rapidly due to advancements in technology, which are improving the speed, accuracy, and ease of performing these tests. Traditional methods of blood typing, which rely on manual agglutination tests, are being supplemented and even replaced by more advanced techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and automated systems. These innovations enable faster and more accurate identification of blood groups, including rare blood types, thereby minimizing the risk of transfusion reactions and improving patient outcomes.

Automation is playing a key role in modernizing blood group typing processes. Automated blood typing systems, which integrate advanced software and robotics, are increasing throughput in clinical laboratories by reducing human error and improving the efficiency of the process. These systems not only provide more accurate results but also allow healthcare providers to handle a larger volume of samples, which is critical in emergency situations or during large-scale blood donation drives. Moreover, point-of-care blood typing devices are being developed, offering immediate and reliable blood type results in settings such as emergency rooms, ambulances, and rural healthcare centers, where traditional lab-based methods may not be feasible.

What Role Does Blood Group Typing Play in Transfusions and Transplants?

Blood group typing plays a critical role in ensuring the safety and success of blood transfusions and organ transplants. Compatibility between the donor and recipient’s blood type is essential to prevent adverse immune reactions, which can be life-threatening. In blood transfusions, mismatched blood types can lead to hemolytic reactions, where the recipient`s immune system attacks the transfused red blood cells, causing severe complications such as kidney failure, shock, or even death. Similarly, in organ transplants, ensuring blood type compatibility is one of the first steps in the donor-recipient matching process to reduce the risk of organ rejection.

In addition to the ABO blood group system, other antigens, such as the Rh factor, Kell, Duffy, and Kidd antigens, are also important for compatibility. Advanced blood group typing techniques now allow for the identification of these minor blood groups, which further enhances the precision of matching for both blood transfusions and transplants. This is particularly important for patients who require frequent transfusions, such as those with sickle cell disease or thalassemia, as they are more likely to develop antibodies against minor blood antigens. The ability to perform extended blood typing, including genotyping, ensures that these patients receive the most compatible blood, reducing the likelihood of transfusion-related complications.

What Factors Are Driving the Growth of the Blood Group Typing Market?

The growth in the blood group typing market is driven by several factors, including the rising demand for blood transfusions, the increasing number of organ transplants, and advancements in diagnostic technologies. The growing prevalence of chronic diseases such as cancer, anemia, and kidney disorders is contributing to a higher demand for blood transfusions, thereby driving the need for accurate and efficient blood group typing. Additionally, the rise in surgical procedures and trauma cases requiring emergency transfusions is further fueling market demand. As the global population ages and healthcare access improves, the need for blood group typing in transfusion medicine is expected to grow.

Technological advancements are also playing a significant role in expanding the market. Automated blood typing systems, molecular typing technologies, and rapid point-of-care devices are improving the accuracy, speed, and efficiency of blood typing, making it easier for healthcare providers to meet the growing demand. Moreover, regulatory guidelines that emphasize the importance of blood group typing in ensuring patient safety are encouraging the adoption of more advanced and standardized testing methods. The increasing awareness about the importance of extended blood typing, particularly for patients requiring regular transfusions, is another factor driving the market. Finally, government initiatives and investments in improving blood donation and transfusion services are supporting the market’s growth, especially in emerging economies.

Select Competitors (Total 33 Featured) -

• Agena Bioscience, Inc.
• AXO Science
• Bag Health Care GmbH
• Beckman Coulter (A Subsidiary of Danaher)
• Bio-Rad Laboratories, Inc.
• Day Medical SA
• Grifols International, S.A.
• Immucor, Inc.
• Merck KGaA
• Novacyt Group

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.